Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
a technology of hematologic disorders and pyrrolidinyl, which is applied in the field of using (+)1, 4dihydro7(3s, 4s)3methoxy4(methylamino)1pyrrolidinyl4oxo1(2thiazolyl)1, 8naphthyridine3carboxylic acid for treatment of antecedent hematologic disorders, can solve the problems of limited efficacy of hematop
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
example 1
Pharmaceutical Composition Suitable for Injection or Intravenous Infusion
[0155]Acidic compositions (
example 2
Clinical Study: Treatment with SNS-595
[0156]A caucasian female patient (81 years old) with MDS that had transformed to refractory CMML was enrolled in this study. The patient was diagnosed about 26 months prior to the study and was given 8 cycles of azacitadine (Vidaza®) about 10 months prior to the study. She was then treated with mitoxantrone+VP16 for 1 cycle, about 4 months prior to the study. The disease had progressed to AML prior to treatment with SNS-595.
[0157]The treatment with SNS-595 was started at 72 mg / m2 (once per week for three weeks, as slow IV push).
[0158]The patient had initial marrow blast count of 39%. The following observations were noted on days 15 and 35.
Peripheral White blood cellAbsolute neutrophilBlasts(WBC) countcount (ANC)Day 15No blasts60094Around Day 35 33%16000 (was 7000 but3139patient had Necrotizingfasciitis (NF) infection)
[0159]The data demonstrates that, although the patient ultimately had progressive disease, the treatment showed clinical benefit w...
example 3
Clinical Study: Treatment with SNS-595
[0160]A black / African-American male patient (58 years old) with relapsed CMML (transformed to AML) was enrolled. The patient was diagnosed about 17 months prior to the study, was treated with 1 cycle of a Southwest Oncology Group (SWOG) regimen after diagnosis. He was given 4 cycles of azacitidine (Vidaza®) about 14 months prior to the study and 1 cycle of decitabine, about 6 months before the study.
[0161]The treatment with SNS-595 was started at 50 mg / m2 (twice a week, as slow IV push). The patient showed initial marrow at baseline 20% blasts.[0162]Post Cycle 1: marrow showed 8% blasts[0163]Post Cycle 2: marrow showed 1% with 4% circulating blasts.[0164]Post Cycle 3: there was 8% circulating blasts.[0165]Post Cycle 4: there was 12% circulating blasts.[0166]At the time of undergoing treatment with third cycle of SNS-595, the patient's absolute neutrophil count (ANC) was 1600.
[0167]The data demonstrates that the treatment showed clinical benefit ...
PUM
Property | Measurement | Unit |
---|---|---|
morphology | aaaaa | aaaaa |
Ph | aaaaa | aaaaa |
weight | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap